Ceftaroline
Indications
Ceftaroline is used for:
Community-acquired pneumonia, Complicated skin and skin structure infections
Adult Dose
Community-Acquired Bacterial Pneumonia
600 mg IV q12hr; infuse over 5-60 minutes for 5-7 days
Skin & Skin Structure Infections
Indicated for acute bacterial skin and skin structure infections, including MRSA
600 mg IV q12hr; infuse over 5-60 minutes for 5-14 days
Child Dose
Community-Acquired Bacterial Pneumonia
Indicated in children aged ?2 months for treatment of community-acquired bacterial pneumonia (CABP) caused by susceptible isolates of the following Gram-positive and Gram-negative microorganisms: Streptococcus pneumoniae (including cases with concurrent bacteremia), Staphylococcus aureus (methicillin-susceptible isolates only), Haemophilus influenzae, Klebsiella pneumoniae, Klebsiella oxytoca, and Escherichia coli
2 months to <2 years: 8 mg/kg IV q8hr x5-14 days
>2 years to <18 years (<33 kg): 12 mg/kg IV q8hr x5-14 days
>2 years to <18 years (>33 kg): 400 mg q8hr OR 600 mg q12hr IV x5-14 days
>18 years: 600 mg IV q12hr; infuse over 5-60 minutes for 5-7 days
Skin & Skin Structure Infections
Indicated in children aged ?2 months for treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible isolates of the following Gram-positive and Gram-negative microorganisms: Staphylococcus aureus (including methicillin-susceptible and -resistant isolates), Streptococcus pyogenes, Streptococcus agalactiae, Escherichia coli, Klebsiella pneumoniae, and Klebsiella oxytoca
2 months to <2 years: 8 mg/kg IV q8hr x5-14 days
>2 years to <18 years (<33 kg): 12 mg/kg IV q8hr x5-14 days
>2 years to <18 years (>33 kg): 400 mg q8hr OR 600 mg q12hr IV x5-14 days
>18 years: 600 mg IV q12hr; infuse over 5-60 minutes for 5-14 days
Renal Dose
Renal impairment
CrCl 31-50 mL/min: 400 mg IV q12hr
CrCl 15-30 mL/min: 300 mg IV q12hr
ESRD (including hemodialysis): 200 mg IV q12hr
Administration
Reconstitution
Add 20 mL of sterile water for inj to a vial containing 400 or 600 mg to provide a 20 or 30 mg/mL soln, respectively. Further dilute reconstituted soln in 50-250 mL (based on patient’s volume requirement) of compatible soln to a final concentration not exceeding 12 mg/mL.
IV Administration
Administer IV injection via volumetric infusion pump
Infuse over 5-60 minutes
Contra Indications
Hypersensitivity to cephalosporins, immediate and severe hypersensitivity to other β-lactam antibacterials (e.g. penicillins, carbapenems).
Precautions
Patient w/ history of non-severe hypersensitivity to other β-lactam antibacterials, seizure disorder. Renal impairment. Pregnancy and lactation.
Pregnancy-Lactation
Pregnancy
No data in pregnant women are available
Animal studies
In developmental toxicity studies conducted in animals, no malformations or other adverse developmental effects were observed in offspring of rats exposed at up to 4 times the maximum recommended human dose (MRHD) during the period of organogenesis through lactation
In rabbits exposed to ceftaroline during organogenesis at levels approximately equal to the MRHD, no drug-induced fetal malformations were observed despite maternal toxicity
Lactation
No data are available regarding presence in human milk, or the effects on breastfed infants or on milk production
Interactions
Adverse Effects
Side effects of Ceftaroline :
1-10%
Diarrhea (5%)
Nausea (4%)
Rash (3%)
Constipation (2%)
Vomiting (2%)
Increased transaminases (2%)
Hypokalemia (2%)
Phlebitis (2%)
Pyrexia (3%)
Pruritus (<3%)
Mechanism of Action
Beta-lactam cephalosporin with activity against aerobic and anaerobic gram-positive and aerobic gram-negative bacteria
Demonstrates activity in vivo against resistant methicillin-resistant Staphylococcus aureus (MRSA) strains and in vitro against vancomycin-resistant and linezolid-resistant S aureus